LUYE PHARMA (02186) Successfully Includes Five New Products in 2025 National Reimbursement Drug List or Commercial Insurance Innovative Drug Directory

Stock News

2025/12/07

LUYE PHARMA (02186) announced that five of its new products have been successfully included in either the "National Reimbursement Drug List (2025)" or the "Commercial Health Insurance Innovative Drug Directory (2025)" issued by the National Healthcare Security Administration.

The five newly included products are: Mephiboxin® (Oxycodone Naloxone Extended-Release Tablets) and Rebalax® (Paliperidone Palmitate Injection (II)), which were newly added to the National Reimbursement Drug List; Zanbika® (Lurbinectedin for Injection) was selected for the Commercial Insurance Innovative Drug Directory; while Betovel® (Goserelin Acetate Microspheres for Injection) and Rekotuo® (Risperidone Microspheres for Injection (II)) were successfully renewed and remain on the National Reimbursement Drug List.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1151283630"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1151283630\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1151283630?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-07 18:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1151283630","market":"nz","top_or_hot":-1,"title":"LUYE PHARMA (02186) Successfully Includes Five New Products in 2025 National Reimbursement Drug List or Commercial Insurance Innovative Drug Directory","media":"Stock News","content":"<p>LUYE PHARMA (02186) announced that five of its new products have been successfully included in either the \"National Reimbursement Drug List (2025)\" or the \"Commercial Health Insurance Innovative Drug Directory (2025)\" issued by the National Healthcare Security Administration.</p>\n<p>The five newly included products are: Mephiboxin® (Oxycodone Naloxone Extended-Release Tablets) and Rebalax® (Paliperidone Palmitate Injection (II)), which were newly added to the National Reimbursement Drug List; Zanbika® (Lurbinectedin for Injection) was selected for the Commercial Insurance Innovative Drug Directory; while Betovel® (Goserelin Acetate Microspheres for Injection) and Rekotuo® (Risperidone Microspheres for Injection (II)) were successfully renewed and remain on the National Reimbursement Drug List.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LUYE PHARMA (02186) Successfully Includes Five New Products in 2025 National Reimbursement Drug List or Commercial Insurance Innovative Drug Directory</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLUYE PHARMA (02186) Successfully Includes Five New Products in 2025 National Reimbursement Drug List or Commercial Insurance Innovative Drug Directory\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2025-12-07 18:46</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>LUYE PHARMA (02186) announced that five of its new products have been successfully included in either the \"National Reimbursement Drug List (2025)\" or the \"Commercial Health Insurance Innovative Drug Directory (2025)\" issued by the National Healthcare Security Administration.</p>\n<p>The five newly included products are: Mephiboxin® (Oxycodone Naloxone Extended-Release Tablets) and Rebalax® (Paliperidone Palmitate Injection (II)), which were newly added to the National Reimbursement Drug List; Zanbika® (Lurbinectedin for Injection) was selected for the Commercial Insurance Innovative Drug Directory; while Betovel® (Goserelin Acetate Microspheres for Injection) and Rekotuo® (Risperidone Microspheres for Injection (II)) were successfully renewed and remain on the National Reimbursement Drug List.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"製藥","start_time":0,"source_url":"","article_id":"1151283630","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1151283630","pubTimestamp":1765104372,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"LUYE PHARMA (02186) announced that five of its new products have been successfully included in either the \"National Reimbursement Drug List (2025)\" or the \"Commercial Health Insurance Innovative Drug...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159992":"创新药","BK1191":"制药","06978":"永泰生物-B","BK1606":"中医药概念","BK1161":"生物科技","BK1574":"生物医药B类股","02186":"绿叶制药","BK1583":"高瓴概念"},"translate_title":"绿叶制药(02186)五款新品成功纳入2025年国家报销药品目录或商保创新药目录","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1,"02186":1,"06978":1},"content_text":"LUYE PHARMA (02186) announced that five of its new products have been successfully included in either the \"National Reimbursement Drug List (2025)\" or the \"Commercial Health Insurance Innovative Drug Directory (2025)\" issued by the National Healthcare Security Administration.\nThe five newly included products are: Mephiboxin® (Oxycodone Naloxone Extended-Release Tablets) and Rebalax® (Paliperidone Palmitate Injection (II)), which were newly added to the National Reimbursement Drug List; Zanbika® (Lurbinectedin for Injection) was selected for the Commercial Insurance Innovative Drug Directory; while Betovel® (Goserelin Acetate Microspheres for Injection) and Rekotuo® (Risperidone Microspheres for Injection (II)) were successfully renewed and remain on the National Reimbursement Drug List.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}